Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > PSSST

<< Previous

Bullboard Posts

Next >>

Comment by Eoganachton Jun 08, 2024 1:28pm

170 Views

Post# 36079335

RE:RE:RE:PSSST

Right!

One other key player is ALA which is used as a PS in PDT for actinic keratosis. It is also used in fluorescence-guided gbm tumour resection as it causes cancer cells to glow, allowing the surgeon a more visible target when resecting.

It is also the only photosensitizer other than Ruvidar/Rutherrin that can cross the bloodbrain barrier. It was used by Dr. Munegowda as a direct comparator with Rutherrin in his study of the efficacy of Rutherrin in rat gbm.

[url=//https://academic.oup.com/noa/article/1/1/vdz006/5499230][/url]

CancerSlayer wrote:
He's trying to stir the pot...

As far as I'm aware, two key players come to the forefront with regards to the photosensitizer realm over the past 30+ years. These include Photofrin & TLD 1433. The former had a promising early response rate (highlighting the potential for PDT), but had two major disadvantages in the form of high-intensity/sunlight-mediated skin toxicity & permanent bladder contraction in a significant percentage (~19%) of trialed patients. Fortunately, many of the disadvantages of early generation photosensitizers are absent with TLD 1433. Photofrin to TLD 1433 may be considered an apple to an orange... JMO.